FDA Approves Eli Lilly’s Tirzepatide for Wider Use in Weight Loss
The U.S. Food and Drug Administration (FDA) has given its official approval for Eli Lilly’s tirzepatide as a treatment for weight loss, expanding its use beyond its initial approval for Type 2 diabetes. This means that adults who are overweight or obese, and who have at least one weight-related condition, can now benefit from this medication.
Prior to this approval, tirzepatide was frequently used off-label for weight loss, as it showed promising results in helping individuals shed excess pounds. The increased demand for tirzepatide, along with other weight loss drugs like Wegovy and Ozempic, has highlighted the pressing need for effective weight loss treatments.
This FDA approval solidifies Eli Lilly’s position as a competitor to Novo Nordisk in the lucrative obesity drug market, which is expected to reach $100 billion by 2030. With an estimated 650 million adults worldwide and nearly 40% of the U.S. adult population affected by obesity, there is a huge market for weight loss medications.
Tirzepatide, marketed as Zepbound, is administered via a weekly injection and requires a gradual dosage increase over a few weeks. The drug works by activating two hormones in the body – GLP-1 and GIP – which help regulate appetite and digestion. Late-stage trials that formed the basis for FDA approval showed significant weight loss among participants who were taking tirzepatide.
Despite the approval, access to tirzepatide and other diabetes and obesity treatments remains a challenge for many individuals. Insurance companies have been dropping coverage for obesity drugs, creating financial barriers for those who need these medications.
Preliminary data suggests that tirzepatide, as well as similar drugs like Wegovy, could potentially have long-lasting benefits for heart health. This is a significant development, as obesity is closely linked to numerous cardiovascular issues.
The list price for tirzepatide is set at $1,059.87 per month, which is around 20% lower than Wegovy. However, actual out-of-pocket costs may vary depending on insurance coverage. Patients are advised to consult with their healthcare providers and insurance companies for more information.
As this story continues to develop, Aha Lifestyle will provide updates on the availability and accessibility of tirzepatide, as well as its potential impact on weight loss and overall health.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”